6 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 2 Phase 3, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow VKA: new trials by email Literature Review of VKA trials Research Report on VKA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) Crovalimab, Placebo, VKA - Antiphospholipid Syndrome | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-03-16 | 2026-03-02 | |
| DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial VKA, Direct Oral Anticoagulant (DOAC) - Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation) | Early Phase 1 | Not yet recruiting | Population Health Research Institute | 100 | 2025-09-03 | 2025-06-08 |
| A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France No OAC, VKA, apixaban - Atrial Fibrillation | Completed | Pfizer | 2140403 | 2023-07-07 | 2025-12-24 | |
| Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity - Antiphospholipid Syndrome, Arterial Thrombosis | Recruiting | McMaster University | 150 | 2022-07-01 | 2025-12-09 | |
| The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial DOAC, VKA - Bleeding Post Cardiac Surgery, Indication for Anticoagulation | Phase 3 | Recruiting | Population Health Research Institute | 3500 | 2021-07-18 | 2026-09-18 |
| Anticoagulation in Patients With Venous Thromboembolism and Cancer Apixaban, Rivaroxaban, Edoxaban - Neoplasms, Embolism | Completed | Pfizer | 1 | 2020-12-14 | 2026-07-24 | |
| The Greek AntiPlatElet Atrial Fibrillation Registry. VKA, NOAC - Atrial Fibrillation, Coronary Artery Disease | Completed | Attikon Hospital | 654 | 2017-12-01 | 2021-07-26 | |
| Health-related Quality of Life in Patients on Anticoagulants DOAC or VKA, VKA - Atrial Fibrillation | Completed | Boehringer Ingelheim | 535 | 2017-04-24 | 2019-04-18 | |
| Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants Apixaban, Rivaroxaban, Heparin - Renal Insufficiency | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 203 | 2016-10-19 | 2022-10-19 |
| Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) apixaban, dabigatran, VKA - Atrial Fibrillation | Completed | Pfizer | 51690 | 2016-02-18 | 2023-06-09 | |
| APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study VKA, Apixaban, dabigatran - Anticoagulation | Completed | Bristol-Myers Squibb | 321501 | 2014-01-01 | 2022-05-18 |
Atrial Fibrillation (5) · Stroke (3) · Antiphospholipid Syndrome (2) · Hemorrhage (2) · Venous Thromboembolism (2) · Coronary Artery Disease (1) · Embolism (1) · Myocardial Infarction (1) · Neoplasms (1) · Pulmonary Embolism (1) · Renal Insufficiency (1) · Venous Thrombosis (1)
Pfizer (3) · Population Health Research Institute (2) · Attikon Hospital (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Hoffmann-La Roche (1) · McMaster University (1)
France (3) · Canada (2) · Spain (2) · Argentina (1) · Australia (1) · Germany (1) · Greece (1) · United Kingdom (1)
Cary Clark (1) · Dimitrios Alexopoulos, MD (1) · Emilie Belley-Cote, MD, MSc (1) · Mireia Canals, +34607550925 (1)
PMID 33034806, PMID 35470214, PMID 36121587, PMID 36410034
2016 (1), 2025 (1)